Abstract Search

ba0003pp315 | Osteoporosis: treatment | ECTS2014

Combination therapy with ibandronate and eldecalcitol enhances bone strength without severe suppression of bone formation in aged ovariectomized rats

Sakai Sadaoki , Takeda Satoshi , Sugimoto Masanori , Shimizu Masaru , Endo Koichi

Ibandronate (IBN), a nitrogen-containing bisphosphonate, and eldecalcitol (ELD), an active vitamin D3 derivative, are used for osteoporosis treatment. Vitamin D3 often used in combination therapies, however, there are no reports on the effects of combined IBN and ELD treatment for osteoporosis.In this study, we examined the effects of combination treatment with IBN and ELD in aged ovariectomized rats. Eight-month-old Wistar-Imamichi...

0 shares

ba0001pp414 | Osteoporosis: treatment | ECTS2013

Treatment with eldecalcitol (ED-71) and raloxifene combined increases cancellous and cortical bone strength in ovariectomized rats

Sakai Sadaoki , Takeda Satoshi , Shiraishi Ayako , Koike Nobuo , Mihara Masahiko , Endo Koichi

Eldecalcitol (ED-71; ELD), a 2β-hydroxypropyloxy derivative of 1α,25(OH)2D3, was approved to treat osteoporosis in Japan in 2011. Raloxifene (RAL), a selective estrogen receptor modulator, is available to treat or prevent postmenopausal osteoporosis. In this study, we compared the effects of combining ELD and RAL against each monotherapy in osteoporotic rats.Eight-month-old female WistarImamichi rats were ovariectomi...

0 shares

ePoster Contact

Bone Abstracts

Combination therapy with ibandronate and eldecalcitol enhances bone strength without severe suppression of bone formation in aged ovariectomized rats

Treatment with eldecalcitol (ED-71) and raloxifene combined increases cancellous and cortical bone strength in ovariectomized rats

BiosciAbstracts